The agreement supports Lavie Bio's 2024
sales growth plan for spring wheat, durum, and barley in
Canada
REHOVOT, Israel, Dec. 5, 2023
/PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene
Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading ag-biologicals
company that develops microbiome-based, computational-driven
bio-stimulant and bio-pesticide novel products, today announced a
distribution agreement exclusive to independent retail with
WinField United Canada for its bio-inoculant seed treatment
Yalos™. This partnership aims to support Lavie Bio's 2024 sales growth strategy in
Canada, with a focus on key
agricultural regions, including Saskatchewan, Alberta, and Manitoba, where Yalos™ targets
spring wheat, durum, and barley crops.
The distribution agreement with WinField United Canada remains
on point with Lavie Bio's strategy,
further advancing the company's sales and distribution capability
throughout Canada and the United
States. Lavie Bio's intent is to engage with additional
complimentary distribution partners to expand its sales reach
throughout North America.
Global cereal grain prices have made it highly economical for
growers to explore innovative ways to increase cereal grain
production. In Lavie Bio's
third-party conducted trials, Yalos™ demonstrated a
yield advantage of 3-4 bushels per acre in wheat, durum, and
barley. The trial data Lavie Bio
compiled over multiple years and unique environmental conditions
illustrates a 4:1 return on investment (ROI) for farmers, given
current market values. Furthermore, Yalos™ requires
minimal change to a farmers' existing seed treatment process and
aligns with the environmental sustainability needs.
Mr. Greg McDonald, President
and General Manager of WinField United Canada, stated:
"WinField United Canada is excited to partner with Lavie Bio in an exclusive independent retailer
distribution agreement on Yalos™. We are committed to
the success of independent retailers across Canada, bringing them unique product offerings
and partnerships such as this one with Lavie Bio. With Lavie Bio's expertise in
biological solutions and WinField United's proven track record in
successfully launching new products and distribution expertise, we
look forward to this new partnership. It further advances our
commitment to drive innovation in crop production across
Canada."
Mr. Russel Putland, EVP
Commercial & GM North America of Lavie
Bio, stated: "I am very pleased with our WinField United
Canada partnership. The distribution agreement expands our market
reach and capability as we launch Yalos™ in
Canada. WinField United Canada has
a proven track record of launching innovative products, which
supports our strategy and the adoption of Yalos™. We
are proud to introduce, together with WinField, a product that will increase
profitability for the Canadian farmer and is also environmentally
friendly."
About Yalos™
Yalos™ is a microbial based inoculant, that has been
designed to empower plant performance based on its ability to
improve the availability and efficiency of nutrient use, thereby
increasing yield, and improving growers' profitability, while
contributing to environmental sustainability and soil health.
Yalos™ is a water dispersible granule (WDG) and is to
be applied as a seed treatment.
About Lavie Bio Ltd.
Lavie Bio, a subsidiary of
Evogene Ltd., aims to improve food quality, sustainability, and
agriculture productivity through the introduction of
microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational
predictive platform, the BDD platform, powered by Evogene's
proprietary MicroBoost AI tech-engine, harnessing the power
of big data, artificial intelligence, and advanced informatics, for
the discovery, optimization and development of bio-inoculant and
bio-pesticide products. For more information, please visit
www.lavie-bio.com.
About Evogene Ltd.
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass
AI and GeneRator AI – leveraging Big Data
and Artificial Intelligence and incorporating deep
multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of
products based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
For more information, please visit: www.evogene.com
About WinField United Canada ULC
WinField United Canada ULC, located in Saskatoon, Saskatchewan, is a wholly owned
subsidiary of Land O'Lakes, Inc., an agriculture and food
co-operative located in Arden Hills,
Minnesota, USA. WinField United Canada is a leading
distribution partner that supports over 350 independently operated
agriculture retail locations across Canada. WinField United Canada supports ag
retailers and their farm customers to access the newest innovations
in adjuvants, biosolutions, crop nutrition, crop protection, and
seed to optimize food production for a growing population.
For more information, please visit WinFieldUnited.ca
Forward Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "intends", "anticipates",
"plans", "believes", "scheduled", "estimates" or words of similar
meaning. For example, Lavie Bio and
Evogene are using forward-looking statements in this press release
when they discuss Lavie Bio's growth
plans in Canada, advancement of
Lavie Bio's sales and distribution
capability throughout Canada and
the United States. Engagement of
additional distribution partners to expand its sales reach
throughout North America and the
increase in the return on investment of farmers by using
YalosTM. Such statements are based on current
expectations, estimates, projections, and assumptions, describe
opinions about future events, involve certain risks and
uncertainties which are difficult to predict and are not guarantees
of future performance. Therefore, actual future results,
performance, or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, the current war between
Israel and Hamas and any worsening
of the situation in Israel such as
further mobilizations or escalation in the northern boarder of
Israel, and .those risk
factors contained in Evogene's reports filed with the applicable
securities authorities. Evogene and its subsidiaries disclaim any
obligation or commitment to update these forward-looking statements
to reflect future events or developments or changes in
expectations, estimates, projections.[ In addition,
Evogene and its subsidiaries rely, and expect to continue to rely,
on third parties to conduct certain activities, such as their
field-trials and pre-clinical studies, and if these third parties
do not successfully carry out their contractual duties, comply with
regulatory requirements or meet expected deadlines, Evogene and its
subsidiaries may experience significant delays in the conduct of
their activities. Evogene and its subsidiaries disclaim any
obligation or commitment to update these forward-looking statements
to reflect future events or developments or changes in
expectations, estimates, projections, and
assumptions.
Evogene Investors' Contact:
Rachel Pomerantz Gerber, Head of
Investor Relations at Evogene
Email: rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/945133/lavie_bio.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/lavie-bio-announces-a-distribution-agreement-with-winfield-united-canada-for-its-bio-inoculant-seed-treatment-yalos-302005815.html
SOURCE Lavie Bio